uniQure (NASDAQ:QURE) Shares Purchased by Quantbot Technologies LP

Quantbot Technologies LP boosted its stake in shares of uniQure (NASDAQ:QUREFree Report) by 1,194.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,600 shares of the biotechnology company’s stock after buying an additional 22,700 shares during the quarter. Quantbot Technologies LP’s holdings in uniQure were worth $165,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Captrust Financial Advisors boosted its stake in uniQure by 1,392.3% during the second quarter. Captrust Financial Advisors now owns 1,940 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,810 shares during the period. PNC Financial Services Group Inc. boosted its stake in uniQure by 152.5% during the first quarter. PNC Financial Services Group Inc. now owns 2,038 shares of the biotechnology company’s stock worth $37,000 after buying an additional 1,231 shares during the period. Roffman Miller Associates Inc. PA acquired a new stake in shares of uniQure during the second quarter worth about $30,000. Covestor Ltd acquired a new stake in shares of uniQure during the first quarter worth about $50,000. Finally, Coppell Advisory Solutions LLC acquired a new stake in shares of uniQure during the second quarter worth about $42,000. Hedge funds and other institutional investors own 73.87% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $28.00 price target on shares of uniQure in a research report on Tuesday, January 16th. The Goldman Sachs Group increased their price target on shares of uniQure from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, November 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of uniQure in a research report on Friday, January 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price target on shares of uniQure in a research report on Wednesday, December 20th. Finally, Mizuho cut shares of uniQure from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $52.00 to $10.00 in a research report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.17.

Read Our Latest Stock Analysis on uniQure

uniQure Stock Performance

Shares of uniQure stock opened at $5.93 on Monday. The firm has a market capitalization of $283.52 million, a P/E ratio of -1.24 and a beta of 1.03. uniQure has a 52 week low of $5.19 and a 52 week high of $22.48. The company has a quick ratio of 9.88, a current ratio of 10.11 and a debt-to-equity ratio of 0.38. The firm’s 50 day moving average is $6.43 and its two-hundred day moving average is $7.08.

uniQure Profile

(Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease.

Recommended Stories

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure (NASDAQ:QUREFree Report).

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.